The report says Acutaas Chemicals beat Q2 estimates on EBITDA/APAT but maintains SELL due to high near-term valuations, with TP of INR 2,427.
Read this note →Acutaas Chemicals Limited
NSE ACUTAAS BSE 543349 INE00FF01025
0 filings · 0 analysed
3,883.30
+2.84%
over 5 days
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 28 Oct 2026, 06:28 | short | 3,793.30 | 2,427.00 | 3,786.60 | 0% | open by 2027-10-28 |
| HDFC Securities | 14 Oct 2026, 15:45 | short | 3,160.50 | 2,266.00 | 3,786.60 | -70% | open by 2027-10-14 |
| HDFC Securities | 21 Sep 2026, 14:27 | short | 3,425.70 | 2,210.00 | 3,786.60 | -30% | open by 2027-09-21 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report expects revenue and EBITDA to grow YoY and QoQ with EBITDA margin broadly stable at 34.2%.
Read this note →The note says HDFC Securities maintains SELL on Acutaas Chemicals with a raised target price of INR 2,210 (from INR 1,569) versus a CMP of INR 3,440, expecting revenue/EBITDA/APAT CAGR of 22/23/21% over FY26-FY29E, RoE declining 214bps to 21.9% by FY29E, and viewing the stock's 64.7/52.3/44.9x FY27/28/29E EPS multiples and ~58x one-year forward PE as contextually high.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief